Generic medications and blood pressure control in diabetic hypertensive subjects

Diabetes Care

Volumn 36, Issue 3, 2013, Pages 591-597

  Cummings, Doyle M ^a   Letter, Abraham J ^b   Howard, George ^b   Howard, Virginia J ^b   Safford, Monika M ^c   Prince, Valerie ^d   Muntner, Paul ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c and Clinical Center   (United States)

^d SAMFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GENERIC DRUG; VASODILATOR AGENT;

AFRICAN AMERICAN; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CAUCASIAN; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DIABETIC HYPERTENSION; DIASTOLIC BLOOD PRESSURE; DRUG LABELING; FEMALE; FOOD AND DRUG ADMINISTRATION; GEOGRAPHY; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HUMAN; INCOME; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTION; RACE DIFFERENCE; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED;

EID: 84874449321     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0755     Document Type: Article

References (21)

1. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl JMed 2010;362: 1575-1585
2. American Diabetes Association. Standards of medical care in diabetesd2011. Diabetes Care 2011;34(Suppl. 1):S11-S61
3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
4. Cummings DM, Doherty L, Howard G, et al. Blood pressure control in diabetes: temporal progress yet persistent racial disparities: national results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. Diabetes Care 2010;33:798-803
5. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-2050
6. Safford MM, Halanych JH, Lewis CE, Levine D, Houser S, Howard G. Understanding racial disparities in hypertension control: intensity of hypertension medication treatment in the REGARDS study. Ethn Dis 2007;17:421-426
7. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-1419
8. Wang YR. Lack of effect of guideline changes on hypertension control for patients with diabetes in the U.S., 1995-2005. Diabetes Care 2007;30:49-52
9. Krousel-Wood M, Muntner P, Carson A, et al. Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines. J Clin Hypertens (Greenwich) 2012;14:277-283
10. Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572
11. Briesacher BA, Andrade SE, Fouayzi H, Chan KA.Medication adherence and use of generic drug therapies. Am J Manag Care 2009;15:450-456
12. Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 2005;25: 135-143
13. National Cholesterol Education Program Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel: detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), final report. Bethesda, MD, National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health, September 2002 (NIH publ. no. 02-5215)
14. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74
15. Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007;29:972-984
16. Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2008;62:338-351
17. Polinski JM, Kilabuk E, Schneeweiss S, Brennan T, Shrank WH. Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. J Am Geriatr Soc 2010;58:1764-1779
18. Heisler M, Hofer TP, Klamerus ML, et al. Study protocol: the Adherence and Intensification of Medications (AIM) studyda cluster randomized controlled effectiveness study. Trials 2010;11:95-108
19. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brandname drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300:2514-2526
20. Stenner SP, Chen Q, Johnson KB. Impact of generic substitution decision support on electronic prescribing behavior. J Am Med Inform Assoc 2010;17:681-688 PubMed
21. Van Wijk BLG, KlungelOH,Heerdink ER, de Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 2006;40:15-20